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Abstract
Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is a predictor of mortality in
critical illness. Severe malaria (SM) is associated with decreased NO bioavailability, but the contribution of ADMA to the
pathogenesis of impaired NO bioavailability and adverse outcomes in malaria is unknown. In adults with and without
falciparum malaria, we tested the hypotheses that plasma ADMA would be: 1) increased in proportion to disease severity, 2)
associated with impaired vascular and pulmonary NO bioavailability and 3) independently associated with increased
mortality. We assessed plasma dimethylarginines, exhaled NO concentrations and endothelial function in 49 patients with
SM, 78 with moderately severe malaria (MSM) and 19 healthy controls (HC). Repeat ADMA and endothelial function
measurements were performed in patients with SM. Multivariable regression was used to assess the effect of ADMA on
mortality and NO bioavailability. Plasma ADMA was increased in SM patients (0.85 mM; 95% CI 0.74–0.96) compared to those
with MSM (0.54 mM; 95%CI 0.5–0.56) and HCs (0.64 mM; 95%CI 0.58–0.70; p,0.001). ADMA was an independent predictor of
mortality in SM patients with each micromolar elevation increasing the odds of death 18 fold (95% CI 2.0–181; p = 0.01).
ADMA was independently associated with decreased exhaled NO (rs =20.31) and endothelial function (rs =20.32) in all
malaria patients, and with reduced exhaled NO (rs =20.72) in those with SM. ADMA is increased in SM and associated with
decreased vascular and pulmonary NO bioavailability. Inhibition of NOS by ADMA may contribute to increased mortality in
severe malaria.
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Introduction
Plasmodium falciparum causes ,1 million deaths annually [1,2].
Despite rapid parasite clearance with the anti-parasitic drug
artesunate, the mortality rate in severe malaria remains high [3,4].
Endothelial activation, parasite sequestration, impaired microvas-
cular perfusion and dysregulated inflammatory responses are all
thought to contribute to severe and fatal malaria [5–9]. Increased
understanding of these pathogenic mechanisms may identify
targets for adjunctive therapies to further improve outcomes.
Severe malaria is associated with impaired nitric oxide (NO)
bioavailability and blood mononuclear cell NO synthase (NOS)
type 2 expression in both children [10,11] and adults [6]. The
concentrations of L-arginine, the substrate for NO production by
all three NOS isoforms [12], are low in children and adults with
severe malaria and likely contribute to the decreased NO
production found in severe disease [6,10,13]. However, in adults
with moderately severe malaria, L-arginine concentrations are at
least as low as those seen with severe malaria, yet there is no
impairment of vascular and pulmonary NO bioavailability as
found in severe disease [6]. This suggests that factors other than
substrate limitation contribute to impaired NO bioavailability in
severe malaria.
Asymmetrical dimethylarginine (ADMA) is a non-specific
endogenous NOS inhibitor which decreases vascular function in
cardiovascular and renal disease [14,15]. Protein-arginine-meth-
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yltransferases methylate arginine residues in proteins and ADMA
is released when these proteins undergo degradation [14]. ADMA
is primarily eliminated by the enzyme dimethylarginine-dimethy-
laminohydrolase-1 (DDAH-1) in the liver and kidney, with ,20%
being excreted in the urine [16]. In adult sepsis, elevated ADMA is
independently associated with increased mortality, a likely
consequence of non-specific inhibition of homeostatic NO
production [17,18]. Increased protein catabolism with hepatic
and renal dysfunction in severe malaria has the potential to
increase ADMA and impair NO production, but the importance
of ADMA in the pathogenesis of malaria is currently unknown.
Clarification of the role of ADMA in malaria is of particular
importance given a recent genome-wide association study in
children linking DDAH polymorphisms with risk of severe malaria
[19], and the potential for the parasite as well as host to produce
ADMA [20].
Acute lung injury is a common but little-studied complication of
severe falciparum malaria associated with high mortality [21]. In
sepsis and critical illness, acute lung injury and mortality are
associated with decreased total and pulmonary NO [22,23].
Pulmonary diffusion capacity and exhaled NO concentrations are
both reduced in severe malaria [6,24], however the causative
factors have not been identified. The role of ADMA in impairing
pulmonary NO bioavailability in severe malaria, or indeed any
critical illness, is not known.
In a prospective longitudinal study of Indonesian adults with
malaria, we evaluated the hypotheses that concentrations of
methylated arginines are independently associated with a) disease
severity, b) reduced exhaled NO and vascular NO bioavailability
and c) increased mortality.
Results
Patients
We measured asymmetrical dimethylarginine (ADMA), sym-
metrical dimethylarginine (SDMA) and L-arginine in 49 patients
with severe malaria, 78 with moderately severe malaria and 19
healthy controls. In the SM patients, 20 patients had only one
criterion for severe disease (coma in 14, hyperbilirubinemia in 4,
respiratory distress in 2) with the remainder having .1 criteria. In
total, 34 of the patients with SM were treated with intravenous
artesunate and the remaining 15 received intravenous quinine [6].
All of the 78 MSM patients were treated with quinine with the
exception of one who received artesunate. Exhaled NO concen-
trations (FeNO) could not be measured in those with coma, but
were possible in 48% (11/23) of non-comatose SM patients, 88%
(69/78) of MSM patients and 100% (19/19) of HCs. RH-PAT
index was measured in all patients with malaria as well as HC.
There were eight deaths among the patients with SM, and none in
the MSM patients. Repeat RH-PAT and venous blood measure-
ments were only performed in one and four of the eight fatal cases
respectively. Baseline characteristics of study participants are
summarized in Table 1.
ADMA, SDMA, L-arginine/ADMA ratio, ADMA/SDMA ratio
and clinical disease
ADMA and SMDA concentrations were increased in SM
patients (0.85 mM; 95% CI 0.74–0.96 and 1.67 mM; 95% CI 1.24–
2.09 respectively) compared to those with MSM (0.54 mM; 95%CI
Author Summary
Severe falciparum malaria is associated with impaired
microvascular perfusion, lung injury and decreased bio-
availability of nitric oxide (NO), but the causes of these
processes are not fully understood. Asymmetrical dimethy-
larginine (ADMA), a competitive endogenous inhibitor of
nitric oxide synthase (NOS), is an independent predictor of
mortality in other critical illnesses, and can impair vascular
function in chronic disease. ADMA can be produced by
both the host and malaria parasites. The major novel
findings of this study in malaria are that ADMA is an
independent predictor of death in falciparum malaria, and
is associated with decreased availability of nitric oxide in at
least two organ systems affected by malaria parasites, the
lining of blood vessels and the lungs. This study
contributes to knowledge of regulation and availability
of pulmonary and endothelial NO in critical illness and
identifies pathogenic processes which may contribute to
death in severe malaria. Therapies which increase the
availability of NO or which reduce ADMA levels may have
potential for adjunctive therapy of severe malaria.
Table 1. Baseline Characteristics of Patients According to Clinical Status.
Healthy controls Moderately-severe malaria Severe malaria
Number 19 78 49
Age; mean (range), y 26 (18–40) 28 (18–56) 29 (18–56)
Males, No. (%) 13 (68) 32 (67) 36 (74)
Weight; mean (range), kg 60 (50–85) 58 (43–77) 57 (45–70)
Ethnicity, No. (%) Papuan highlander* 17 (89) 59 (77) 27 (55)
Current smoker, No. (%) 9 (47) 31 (40) 22 (45)
Days of fever before presentation; median (IQR){ Nil 2 (1–5) 4 (1–7)
Systolic blood pressure; mean (range), mmHg{ 128 (112–138) 110 (80–134) 105 (60–154)
Pulse rate; mean (range), beats/minute{ 67 (48–91) 81 (54–118) 98 (61–138)
Respiratory rate; mean (range), breaths/minute{ 19 (18–23) 23 (16–32) 30 (16–60)
Temperature; mean (range), uC{ 35.6 (35.1–36.8) 36.5 (34.8–40.2) 37.2 (34.8–40.3)
* p,0.01 calculated by x2 test.
{ p,0.01 calculated by ANOVA or two sided t test.
IQR, interquartile range.
doi:10.1371/journal.ppat.1000868.t001
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0.5–0.56 and 0.58 mM; 95%CI 0.54–0.63) and HC (0.64 mM;
95%CI 0.58–0.70 and 0.53 mM; 95%CI 0.47–0.59); ANOVA
p,0.001 for both ADMA and SDMA, Table 2, Figure 1A and
1B. L-arginine concentrations were significantly higher in HCs
compared to patients with MSM and SM, with the L-arginine/
ADMA ratio decreasing with increasing disease severity (p,0.001;
Table 2).
ADMA, SDMA, L-arginine/ADMA ratio and exhaled nitric
oxide concentrations
Exhaled nitric oxide concentration (FeNO) was significantly
decreased in SM patients compared to MSM and HC; (Table 2).
FeNO was inversely correlated with plasma ADMA concentration
(rs =20.31, p= 0.003; Table 3) in all malaria patients, and in the
subgroup of 11 patients with SM (rs =20.72, p= 0.01; Table 3).
FeNO also correlated inversely with HRP2 concentration
(rs =20.51, p,0.001) in malaria patients, but not in the SM
group. FeNO remained inversely associated with ADMA, after
adjusting for disease severity, creatinine and HRP2. FeNO was not
associated with SDMA, the L-arginine/ADMA ratio, plasma
hemoglobin or arginase.
ADMA, SDMA, L-arginine/ADMA ratio and endothelial
function
As reported previously, the RH-PAT index was significantly
lower in SM patients compared to those with MSM and controls
(p,0.001) Table 2. In all malaria patients, there were moderate
inverse associations between RH-PAT index and ADMA
(rs =20.32; p,0.001; Table 3) and SDMA (rs =20.35;
p,0.001) concentrations. After adjusting for factors previously
shown to be associated with RH-PAT index including plasma
hemoglobin [6,7,25], the inverse association with ADMA
remained significant, with the final model including both ADMA
and cell free hemoglobin (r = 0.40). In contrast, the L-arginine/
ADMA ratio was not associated with the RH-PAT index.
Longitudinally there was no association between the RH-PAT
index and ADMA concentration or L-arginine/ADMA ratio in
SM patients.
ADMA, SDMA, L-arginine/ADMA ratio and markers of
endothelial activation
Patients with SM had significantly elevated plasma concentra-
tions of Ang-2, ICAM-1 and E-selectin compared to those with
MSM and HC; Table 2. Angiopoietin-2 and ICAM-1 were
significantly correlated with both ADMA (rs = 0.48 and 0.42
respectively; p,0.001; Table 3), and SDMA (rs = 0.54 and 0.52;
p,0.001), and this was also apparent in the subgroup of SM
patients; Table 3. ADMA remained independently associated
with Ang-2 and ICAM-1 after adjusting for confounding factors,
including creatinine, plasma hemoglobin, parasite biomass and
disease severity.
There was no significant correlation between ADMA or SDMA
with E-selectin, and none between the L-arginine/ADMA ratio
and Ang-2, ICAM-1 and E-selectin.
ADMA, SDMA, L-arginine/ADMA ratio and biomarkers of
severity
The plasma creatinine, total bilirubin, P. falciparum histidine rich
protein 2 (HRP2) and venous lactate were increased in SM
compared to MSM (Table 2). In all patients with malaria, there
were correlations between ADMA and SDMA with creatinine
(rs = 0.45; p,0.001; rs = 0.69; p,0.001; Table 3), total bilirubin
Table 2. Baseline Laboratory and Physiological Measurements According to Clinical Status.
Healthy controls Moderately-severe malaria Severe malaria
Number 19 78 49
White blood cell count; mean (95% CI), x 103ml21* ND 5.9 (5.4–6.9) 9.5 (8.5–10.5)
Hemoglobin; mean (range), g/L* ND 121 (70–170) 109 (60–163)
Plasma cell-free hemoglobin; median (IQR), mM{ 1.3 (0.74–2.4) 2.6 (1.3–4.5) 5.4 (3.2–7.4)
Exhaled NO concentrations; median (IQR), ppb{ 16.0 (9.5–19.3) 16.1 (10.7–25.3) 10.5 (7.5–15)
RH-PAT Index; mean (95%CI)* 1.87 (1.58–2.17) 1.82 (1.71–1.93) 1.37 (1.32–1.42)
Plasma creatinine; mean (95%CI), mmol/L* ND 88 (82–94) 286 (207–365)
Plasma total bilirubin; mean (95%CI), mmol/L* ND 16.7 (12.9–20.4) 95.2 (47.7–142.6)
Lactate concentration; mean (95%CI), mmol/L* ND 1.4 (1.2–1.6) 2.93 (2.3–3.5)
Parasite density, geometric mean (range), ml21* ND 14,900 (850–127,000) 35,100 (125–725,000)
HRP2 concentration; mean (range), loge ng/ml* ND 5.75 (1.34–8.79) 8.08 (1–10.98)
Soluble ICAM-1; mean (95%CI), pg/ml* ND 569 (516–623) 938 (792–1084)
Soluble E-selectin; mean (95%CI), pg/ml* ND 106 (95–118) 153 (113–193)
Plasma Angiopoietin-2; mean (95%CI), pg/ml* 2,800 (2,000–3,500) 6,500 (5,000–8,000) 17,000 (14,000–22,000)
Plasma ADMA; mean (95%CI), mmol/L* 0.64 (0.58–0.70) 0.55 (0.5–0.56) 0.85 (74–0.96)
Plasma SDMA; mean (95%CI), mmol/L* 0.53 (0.47–0.59) 0.58 (0.54–0.63) 1.67 (1.24–2.09)
Plasma L-arginine concentration; mean (95%CI) mmol/L* 77 (65–88) 41 (37–44) 49 (43–56)
L-arginine/ADMA ratio; mean (95%CI)* 121 (107–135) 78 (71–86) 64 (56–71)
Plasma Arginase; mean (95%CI), mmol/ml/h* 0.14 (0.08–0.17) 0.20 (0.14–0.24) 0.26 (0.22–0.31)
* p,0.01 calculated by ANOVA (overall) or two sided t test. ND, not measured.
{ p,0.05 calculated by Kruskal-Wallis test.
IQR, Interquartile Range.
doi:10.1371/journal.ppat.1000868.t002
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(rs = 0.32; p,0.001; rs = 0.36; p,0.001; Table 3), HRP2
(rs = 0.46; p,0.001; rs = 0.62; p,0.001; Table 3) and lactate
(rs = 0.3; p = 0.01; rs = 0.29, p= 0.02; Table 3). The associations
remained significant in SM patients for each of these biomarkers of
disease severity except for venous lactate (Table 3). There was no
association between L-arginine/ADMA ratio and any biomarker.
TNF was only measured in the SM patients, and was associated
with SDMA (rs = 0.52; p = 0.001), but not with ADMA (p= 0.06).
ADMA, SDMA, L-arginine/ADMA ratio and mortality
In SM patients, ADMA and SDMA concentrations were
significantly higher in the 8 patients who died (1.28 mM; 95%CI
0.88–1.74 and 3.76 mM; 95%CI 1.88–5.56, respectively) com-
pared to the 41 survivors (0.77 mM; 95%CI 0.64–0.84 and 1.27
mM; 95%CI 0.99–1.54, respectively; p,0.001; Figure 1A and
1B).
Each micromolar increase in ADMA and SDMA concentra-
tions was associated with an 18-fold (OR 18.8 95% CI 2.0–181;
p = 0.01) and three-fold (OR 3.0; 95% CI 1.5–6.2; p = 0.002)
increased risk of death, respectively. ADMA but not SDMA
remained a significant risk factor for death after adjusting for other
confounding factors, such as Ang-2, creatinine, parasite biomass,
bilirubin, base deficit and lactate. A final model predicting a fatal
outcome included ADMA, Ang-2, HRP2 and creatinine
(Table 4). The L-arginine/ADMA ratio was not associated with
risk of death.
The prognostic value of ADMA in predicting a fatal outcome
was measured by the area under the receiver operating curve
(ROC). ADMA (AUROC 0.85; 95% CI 0.71–0.99; Figure 2) was
comparable to other reliable prognostic indicators, including Ang-
2 (AUROC 0.84; 95% CI 0.71–0.96), HRP2 (AUROC 0.86; 95%
CI 0.73–0.94), base deficit (AUROC 0.73; 95% CI 0.53–0.92),
and TNF (AUROC 0.71; 95% CI 0.43–0.98), and a better
predictor of fatal outcome than venous blood lactate (AUROC
0.63; 95%CI 0.41–0.83; p= 0.003).
Longitudinal Course of ADMA, SDMA and L-arginine/
ADMA ratio
In patients with severe malaria, there was no significant change
in ADMA (Figure 3A) or SDMA concentrations during the
course of hospitalization among the overall group, survivors or
those with a fatal outcome. Among survivors, there was a daily
increase in L-arginine/ADMA (b=9.1, p,0.001; Figure 3B) but
no increase in those who died.
Table 3. Correlation Coefficients (Rs) for ADMA and Physiological Measures/Biomarkers of Severity.
All malaria patients Severe malaria
Correlation (rs) p df
* Correlation (rs) p df
*
ADMA RH-PAT Index 20.32 0.001 139 20.22 0.18 48
Exhaled NO 20.31 0.003 79 20.72 0.01 10
Lactate 0.30 0.01 124 0.1 0.3 48
HRP2 0.40 ,0.001 109 0.42 0.004 44
ICAM-1 0.42 ,0.001 109 0.61 ,0.001 47
E-selectin 0.12 0.4 116 0.20 0.10 47
Ang-2 0.48 ,0.001 140 0.56 ,0.001 48
TNF 0.29 0.06 39
Creatinine 0.45 ,0.001 117 0.55 ,0.001 47
Total Bilirubin 0.32 ,0.001 115 0.58 ,0.001 47
*df = degrees of freedom.
doi:10.1371/journal.ppat.1000868.t003
Figure 1. Plasma dimethylarginine concentrations in each
group on enrollment (ANOVA: p,0.001). A. Plasma asymmetric
dimethylarginine (ADMA) concentrations in each group on enrollment
(ANOVA: p,0.001). In the severe malaria group, open circles represent
fatal cases and closed circles survivors. Horizontal lines indicate mean
for each group. B. Plasma symmetric dimethylarginine (SDMA)
concentrations in each group on enrollment (ANOVA: p,0.001). In
the severe malaria group, open circles represent fatal cases and closed
circles survivors. Horizontal lines indicate mean for each group.
doi:10.1371/journal.ppat.1000868.g001
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Discussion
ADMA is increased in severe falciparum malaria and is an
independent predictor of mortality. Indeed ADMA was a better
predictor of death than blood lactate, previously shown to be a
reliable prognostic indicator of increased mortality in severe
malaria [26]. Our study demonstrated that elevated plasma
ADMA concentrations are independently associated with de-
creased exhaled NO concentrations, impaired vascular NO
bioavailability, increased endothelial activation and parasite
Table 4. Factors Associated with Death in Severe Malaria Patients.
Risk Factors Univariate Model Final Model
Odds Ratio 95%CI P Odds Ratio 95%CI P
ADMA (mmol/L) 18.8 2.0–181 0.010 229 2.9–2675 0.025
Creatinine (mmol/L) 1.004 1.001–1.007 0.005 1.006 1.001–1.01 0.025
Angiopoietin 2 (pg/ml) 1.00058 1.00003–1.00109 0.024 1.00009 1.000002–1.0008 0.048
HRP2 (ng/ml) 1.00082 1.00009–1.001 0.01 1.0001 1.00002–1.002 0.017
Standard Base Deficit 1.19 1.01–1.4 0.037 0.93 0.64–1.35 0.659
Lactate (mmol/L) 1.32 1.02–1.41 0.044 1.29 0.51–3.3 0.485
Total Bilirubin (mmol/L) 1.006 1.001–1.009 0.015 1.003 0.98–1.1 0.21
doi:10.1371/journal.ppat.1000868.t004
Figure 2. Top panel is the nonparametric receiver operating
curve (ROC) assessing asymmetrical dimethylarginine (AUROC,
0.85; 95%CI 0.71–0.99) and the bottom panel venous lactate
(AUROC 0.63; 95%CI 0.41–0.83) as prognostic markers for
mortality in severe malaria (p=0.003).
doi:10.1371/journal.ppat.1000868.g002
Figure 3. Longitudinal course of plasma ADMA concentrations
and L-arginine/ADMA ratio in patients with severe malaria.
Mean values (circles) and 95%CI (bars) are displayed at each time point.
Values from day 5–14 indicate mean of all values obtained during this
period. X axis values show time from start of anti-malarial therapy.
Numbers indicate patients examined during each time period.
doi:10.1371/journal.ppat.1000868.g003
Asymmetrical Dimethylarginine and Malaria
PLoS Pathogens | www.plospathogens.org 5 April 2010 | Volume 6 | Issue 4 | e1000868
biomass. To our knowledge this is the first demonstration of a
relationship between increased ADMA and impaired exhaled NO
in any critical illness. Taken together, these findings suggest that
ADMA, an endogenous inhibitor of all three nitric oxide synthase
(NOS) isoforms, reduces NO bioavailability in at least two organ
systems and may contribute to increased mortality in falciparum
malaria.
In critically ill patients, elevated ADMA concentrations are
likely to result from increased production and reduced
elimination. The elevation in both ADMA and SDMA may
result from increased host production of methylated arginines in
severe malaria. The majority of circulating ADMA is taken up
by the liver before being metabolized by dimethylarginine-
dimethylaminohydrolase-1 (DDAH-1); approximately 20% is
excreted unchanged in the urine [16]. Hepatic blood flow is
known to be significantly impaired in severe malaria [27]. The
correlation of bilirubin and creatinine with increased ADMA,
suggests that similar to sepsis [28], decreased hepatic and renal
elimination may also increase ADMA concentrations in severe
malaria. The large parasite biomass in severe malaria may also
be a potential source of ADMA, with Plasmodium falciparum
possessing protein arginine methyltransferases capable of pro-
ducing ADMA [20]. The significant independent correlation
between parasite biomass and ADMA on admission suggests this
may be occurring in vivo, although the persistently elevated levels
in severe malaria after commencement of anti-malarial therapy
suggest the importance of altered host production and clearance
in the post-treatment period. Increased clearance due to
increases in either hepatic blood flow or DDAH activity may
explain the decreased ADMA concentrations in patients with
moderately severe malaria. There are no clinical studies to date
documenting increased DDAH activity in mild inflammatory
diseases, but hepatic blood flow is known to be significantly
increased in acute uncomplicated falciparum malaria compared
to patients with severe disease and healthy individuals [27]. The
converse may also be true, with lower plasma ADMA
concentrations potentially increasing vascular NO bioavailability
in moderately severe malaria [14], and possibly contributing to
elevated hepatic blood flow.
The loss of DDAH-1 function in a murine model of sepsis
increased ADMA, reduced NO signaling, and worsened vascular
pathophysiology including endothelial function [29]. In human
severe sepsis, a polymorphism in the DDAH-2 enzyme increased
ADMA levels which were associated with increased severity of
organ failure and early septic shock [30]. Recently, a genome-wide
association study in children found that a polymorphism in the
gene encoding DDAH-1 was associated with an increased
likelihood of severe malaria [19]. These studies indicate that
altered DDAH function may be a contributor to organ damage
and increased mortality in severe malaria as well as in other critical
illnesses.
SDMA does not inhibit NOS, but competes with plasma L-
arginine for intracellular uptake by the cationic amino acid
transporters (CAT). Unlike ADMA, it is not metabolized by
DDAH and is almost exclusively eliminated by the kidneys [16]. In
chronic disease SDMA has recently been shown to be an
independent predictor for major cardiovascular events in certain
chronic diseases [31]. We find that in malaria, SDMA concen-
trations are associated with mortality and decreased vascular
bioavailability on univariate analysis, but not after adjusting for
renal function. While the association between SDMA and disease
severity is likely to reflect the degree of renal impairment and
SDMA retention, it is possible that retained SDMA may also
contribute to decreased NO bioavailability in severe malaria.
In critically ill adults with organ failure and severe sepsis,
ADMA concentrations are associated with increased all-cause
mortality and the severity of organ failure [17,30]. Investigators
have hypothesized that this may result from non-selective
inhibition by ADMA of all three isoforms of NOS, particularly
homeostatic NOS3 (endothelial NOS) [18]. This is similar to the
postulated mechanism to explain the increased mortality with use
of NG-monomethyl-arginine (NMMA), another non-specific NOS
inhibitor, in a phase 3 clinical trial of sepsis [32]. In falciparum
malaria, systemic NO production is impaired in severe disease and
hypoargininemia is likely to be a contributing cause [6,10,11,13].
Exhaled and vascular NO are both reduced in adults with severe
malaria [6], but not in moderately severe malaria (MSM) despite
similar degrees of hypoargininemia [6]. This may be explained by
the higher ADMA in severe malaria and a greater competitive
inhibition of NOS in SM compared to MSM, similar to clinical
studies of healthy volunteers in which ADMA infusion reduced
blood flow [15,33]. In mouse studies, ADMA infusion alone
reduces splenic blood perfusion, but when combined with
hypoargininemia, causes a reduction in renal, hepatic and splenic
blood flow with organ damage [34]. Regulation of microcircula-
tory flow is dependent on pre-capillary arteriolar vasodilatory
responses which in turn are critically dependent on NO
production [35], with both likely to be decreased by ADMA in
SM. By decreasing functional capillary density, ADMA could
further impair microcirculatory function already compromised by
parasite sequestration in capillaries and post-capillary venules [36].
We have previously shown that hemolysis-related NO quench-
ing by cell-free hemoglobin is associated with reduced vascular
NO bioavailability in severe malaria [25]. In malaria, increased
ADMA and cell-free hemoglobin were independently related to
endothelial dysfunction, suggesting that inhibition of NOS and
NO quenching both reduce vascular NO bioavailability.
NO has multiple regulatory functions that maintain endothelial
quiescence in vitro, including inhibition of endothelial Weibel-
Palade body (WPB) exocytosis and ICAM-1 expression [37,38].
Plasma concentrations of angiopoietin-2 (Ang-2), an angiogenic
factor stored in WPBs, predict increased mortality in malaria [7],
and ICAM-1 is a major endothelial adhesion receptor mediating
cytoadherence of parasitized red cells and microvascular seques-
tration [5]. We demonstrate that ADMA levels correlate with
increased Ang-2, but the association between ADMA and
increased mortality is independent of Ang-2, suggesting effects of
NO inhibition in addition to increased WPB exocytosis.
Acute lung injury is a complication of severe malaria in adults
associated with a high mortality rate [21,24]. Gas transfer at the
alveolar-capillary membrane and exhaled NO are both decreased
in severe falciparum malaria [6,24]. In an animal model of
sepsis–associated pulmonary injury, non-selective NOS inhibition
causes increased lung edema [39]. Clinical studies have shown
decreased pulmonary NO concentrations in patients with acute
respiratory distress syndrome, as well as an association between
decreased NO production and a worse outcome in acute lung
injury [22,23]. The lung is a major source of ADMA and
increased concentrations are associated with pulmonary arterial
hypertension [40,41]. In severe malaria, both ADMA and
parasite biomass are strongly inversely associated with exhaled
NO concentrations, suggesting that both factors impair pulmo-
nary NO production in severe disease.
There are several limitations in our study. Measurement of
exhaled NO was not possible in patients with coma and was
possible in only half of severe malaria patients without coma. Our
results may therefore not reflect the relationship between ADMA
and exhaled NO in all syndromes of severe malaria. In patients
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who died, only 4 of 8 had at least one repeat blood sample, and
the longitudinal data may not truly reflect the course of the
methylated arginines in fatal cases. RH-PAT index is at least 50%
dependent on endothelial NO release [42], but we cannot
exclude an effect of ADMA on other vasodilators such as
prostacyclin and endothelium-derived hyperpolarizing factor.
Although we have measured plasma ADMA concentrations, the
effects of ADMA are intracellular. Nevertheless, in vitro studies
with endothelial cells have shown that increasing extracellular
ADMA results in five-fold increases in intracellular concentra-
tions. This suggest that intracellular concentrations of ADMA in
severe malaria may be higher, and may be adequate for
meaningful inhibition of for all three NOS isoforms (IC50s ,2-
5mM) [43]. The observational nature of the study does not allow
us to conclude with certainty a direct role for ADMA in the
pathophysiology of severe malaria. While the association of
ADMA with mortality may reflect impaired renal and hepatic
function, it remained significant after adjusting for these factors in
a multivariable model. Furthermore, increased ADMA from
impaired hepatic and/or renal clearance is not just a marker of
organ dysfunction in critical illness, with retained ADMA having
functional consequences on NOS activity.
In summary, the endogenous non-selective NOS inhibitor
ADMA is elevated in SM and is an independent risk factor for
mortality. ADMA is also associated with decreased FeNO and
vascular NO bioavailability, as well as increased endothelial
activation and parasite biomass. Therapies which increase NO
bioavailability or which diminish ADMA levels represent rational
approaches for interventional trials of adjunctive therapy in severe
malaria.
Methods
Study site and patients
The study was conducted at Mitra Masyarakat Hospital,
Timika, Papua, Indonesia, a region with unstable transmission
of multidrug resistant malaria [44,45]. Written informed consent
was obtained from all patients, if they were comatose or too ill,
consent was obtained from relatives. The Ethics Committees of the
National Institute of Health Research and Development, Indone-
sia, and Menzies School of Health Research, Australia approved
the study.
Patients were $18 years old with moderately-severe (MSM) or
severe (SM) Plasmodium falciparum malaria without P. vivax infection
and with a hemoglobin level.60 g/L who had been prospectively
enrolled in a study of endothelial dysfunction and exhaled NO [6].
Previous results from this study group have been published
[6,7,13,25]. Briefly, SM was defined as P. falciparum parasitemia
and $1 modified WHO criterion of severity (excluding severe
anemia). MSM was defined as fever within the preceding
48 hours, .1,000 asexual P. falciparum parasites/mL, no WHO
warning signs or severe malaria criteria and a requirement for
inpatient parenteral therapy because of inability to tolerate oral
treatment. Healthy controls (HC) were non-related hospital
visitors with no history of fever in last 48 hours, intercurrent
illness or smoking in last 12 hours, or evidence of parasitemia [6].
Standardized history and physical examination were documented.
Heparinized blood was collected daily, centrifuged within 30
minutes of collection and plasma stored at 270uC. Parasite counts
were determined by microscopy. Hemoglobin, biochemistry, acid-
base parameters and lactate were measured with a bedside
analyser (i-STAT Corp). Patients were treated with anti-malarials
and antibiotics using standard national protocols as previously
described [6].
L-arginine, asymmetrical dimethylarginine and
symmetrical dimethylarginine
Solid phase extraction (SPE) of amino acids was followed by
derivatisation with Accq-Fluor and separation on a Gemini-NX
column at pH 9 [46]. The SPE method gives absolute recoveries
of .80% for ADMA and symmetrical dimethylarginine (SDMA)
and average relative recoveries of 102% for ADMA and 101% for
SDMA. The HPLC method gives intra-assay RSDs of 2.1% and
2.3% and inter-assay RSDs of 2.7% and 3.1% for ADMA and
SDMA respectively [46].
Cell-free hemoglobin, cytokines, endothelial activation,
arginase and L-arginine
Plasma concentrations of cell-free hemoglobin and the endo-
thelial activation markers, ICAM-1, E-selectin and angiopoietin-2
were measured by ELISA as previously reported in this population
[6,7,25]. Total parasite biomass was quantified by measuring
plasma histidine rich protein-2 (HRP2) by ELISA [6], plasma
arginase by a radiometric method [6] and plasma TNF
concentrations by flow cytometry, as previously reported [7].
Endothelial function and pulmonary nitric oxide
Endothelial function was measured non-invasively using
peripheral arterial tonometry (EndoPAT) by the change in digital
pulse wave amplitude in response to reactive hyperemia, giving a
RH-PAT Index as reported previously [6]. The RH-PAT index is
at least 50% dependent on endothelial NO production [42].
Endothelial function was measured daily until death or discharge,
or until the RH-PAT index was above an a priori cutoff (1.67) for
two consecutive days [13]. Fractional concentrations of exhaled
NO were measured by NO analyser (Aerocrine), as previously
described, using American Thoracic Society guidelines and a flow
rate of 250 ml/sec [6].
Statistical methods
Statistical analysis was performed with STATA 9.2 software.
Intergroup differences were compared by ANOVA or Kruskal-
Wallis test, where appropriate. Pearson’s or Spearman’s correla-
tion coefficients were determined depending on normality of
distributions. Multiple stepwise linear regression was used to adjust
for confounding variables. Longitudinal associations were assessed
by mixed effects modeling using generalized estimating equations.
Logistic regression was used to determine the association between
death and ADMA concentrations. Variables hypothesized, as well
as those shown in previous publications [6,7,25], to contribute to
mortality, pulmonary NO and endothelial pathology were
included in a multiple regression model if p,0.05 on univariate
analysis and retained if they remained significant. Goodness-of-fit
was assessed by the Hosmer-Lemeshow goodness of fit test and
independent variables tested for interactions. The prognostic
utility of continuous variables was measured using the area under
the receiver operating curves (ROCs) and its 95% confidence
intervals were calculated. A two-sided value of p,0.05 was
considered significant.
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